JenaValve Technology’s recent spotlight at New York Valves 2025 underscored the growing impact and clinical relevance of its Trilogy™ Transcatheter Heart Valve (THV) System, particularly in the treatment of aortic regurgitation (AR). Traditionally, AR has posed a significant therapeutic challenge, especially in patients ineligible for open-heart surgery. The Trilogy system’s ability to address native AR and complex cases such as left ventricular assist device (LVAD)-associated AR showcases its innovation in filling a long-standing treatment gap. Through two live broadcasted procedures, the system demonstrated real-time success in improving valve function without the need for invasive surgery, highlighting the practical utility of its unique anchoring and sealing mechanisms tailored specifically for AR anatomy.

The purpose behind announcing these live clinical highlights is twofold: to increase awareness among global cardiology communities and to showcase the Trilogy system’s potential beyond conventional transcatheter aortic valve replacement (TAVR) indications. By broadcasting these real-world procedures—including a native AR case from Leeds General Infirmary and an LVAD-associated AR case from New York Presbyterian Hospital—JenaValve is advancing both physician education and clinical validation. These cases also contribute critical data to the ongoing ALIGN-AR program and JENA-VAD Registry, supporting regulatory pathways and demonstrating procedural safety, feasibility, and patient outcomes across a wider spectrum of complex heart failure populations.

As JenaValve moves forward, the clinical momentum generated at New York Valves 2025 paves the way for future trials, broader adoption, and potential regulatory approvals in key markets. With the LVAD AR patient population growing and treatment options remaining limited, Trilogy’s early success positions it as a game-changing therapy with life-saving implications. The company’s commitment to expanding access, generating evidence, and engaging interventional cardiologists through live demonstrations reflects a strong strategic vision aimed at redefining transcatheter solutions for underserved cardiac conditions.